Cite
HARVARD Citation
Rummel, M. et al. (n.d.). Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet oncology. 17 (1), pp. 57-66. [Online].